XGN Quote, Financials, Valuation and Earnings

Insight Molecular Diagnostics, Inc. has a net margin of -41.1% compared to Exagen, Inc.'s net margin of -4174.62%. Exagen, Inc.'s return on equity of -140.03% beat Insight Molecular Diagnostics, Inc.'s return on equity of -1008.03%.

Exagen, Inc. has a consensus price target of $14.71, signalling upside risk potential of 219.88%. On the other hand Insight Molecular Diagnostics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 7.36%. Given that Exagen, Inc. has higher upside potential than Insight Molecular Diagnostics, Inc., analysts believe Exagen, Inc. is more attractive than Insight Molecular Diagnostics, Inc..

Exagen, Inc. has a beta of 1.863, which suggesting that the stock is 86.324% more volatile than S&P 500. In comparison Insight Molecular Diagnostics, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.885%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. Insight Molecular Diagnostics, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $17.2M, which are larger than Insight Molecular Diagnostics, Inc. quarterly revenues of $260K. Exagen, Inc.'s net income of -$7.1M is higher than Insight Molecular Diagnostics, Inc.'s net income of -$10.9M. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while Insight Molecular Diagnostics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.46x versus 39.67x for Insight Molecular Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

ProPhase Labs, Inc. has a net margin of -41.1% compared to Exagen, Inc.'s net margin of -774.52%. Exagen, Inc.'s return on equity of -140.03% beat ProPhase Labs, Inc.'s return on equity of -90.24%.

Exagen, Inc. has a consensus price target of $14.71, signalling upside risk potential of 219.88%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 37958.47%. Given that ProPhase Labs, Inc. has higher upside potential than Exagen, Inc., analysts believe ProPhase Labs, Inc. is more attractive than Exagen, Inc..

Exagen, Inc. has a beta of 1.863, which suggesting that the stock is 86.324% more volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $17.2M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. Exagen, Inc.'s net income of -$7.1M is lower than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.46x versus 0.25x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of -41.1% compared to Exagen, Inc.'s net margin of 14.51%. Exagen, Inc.'s return on equity of -140.03% beat Veracyte, Inc.'s return on equity of 2.52%.

Exagen, Inc. has a consensus price target of $14.71, signalling upside risk potential of 219.88%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.67 which suggests that it could grow by 12.77%. Given that Exagen, Inc. has higher upside potential than Veracyte, Inc., analysts believe Exagen, Inc. is more attractive than Veracyte, Inc..

Exagen, Inc. has a beta of 1.863, which suggesting that the stock is 86.324% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $17.2M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. Exagen, Inc.'s net income of -$7.1M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 111.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.46x versus 6.79x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of -41.1% compared to Exagen, Inc.'s net margin of -2.87%. Exagen, Inc.'s return on equity of -140.03% beat XWELL, Inc.'s return on equity of -224.93%.

Exagen, Inc. has a consensus price target of $14.71, signalling upside risk potential of 219.88%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1927.81%. Given that XWELL, Inc. has higher upside potential than Exagen, Inc., analysts believe XWELL, Inc. is more attractive than Exagen, Inc..

Exagen, Inc. has a beta of 1.863, which suggesting that the stock is 86.324% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.

Exagen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Exagen, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Exagen, Inc. quarterly revenues are $17.2M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. Exagen, Inc.'s net income of -$7.1M is lower than XWELL, Inc.'s net income of -$211K. Notably, Exagen, Inc.'s price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Exagen, Inc. is 1.46x versus 0.06x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.